Ahead of June's American Society of Clinical Oncology (ASCO) meeting in Chicago, an abstract related to the data to be unveiled by Jounce Therapeutics Inc. so alarmed Wall Street that the company's shares lost 35 percent of their value, and the situation worsened when the data rolled out. But there may be cause to maintain hope for JTX-2011, the agonist of inducible T-cell co-stimulator (ICOS), a protein on the surface of certain T cells that Jounce believes can stimulate an immune response against solid tumors.